Navigation Links
Omeros Corporation Reports Third Quarter 2013 Financial Results
Date:11/7/2013

FDA for the treatment of Huntington's disease.
  • Reported positive clinical data from its Phase 1 clinical trial of OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), an important regulator of the lectin pathway of the immune system. A Phase 2 clinical program to evaluate OMS721 in the treatment of thrombotic microangiopathies (TMAs), a family of disorders that occurs in the microcirculation of the body's organs, most commonly the kidney and brain, is expected to begin enrollment in early 2014.
  • Announced that its proprietary Cellular Redistribution Assay technology had "unlocked" six additional Class A orphan G protein-coupled receptors (GPCRs) for drug development, bringing the total number of Class A orphan GPCRs "unlocked" by Omeros to 52. These six orphan GPCRs are linked to a series of important indications, including cardiovascular indications, certain types of cancer and Grave's disease. Omeros also announced that it had identified small molecules that interact with two non-orphan Class B GPCRs, the glucagon-like peptide 1 receptor (GLP-1R) and the parathyroid hormone 1 receptor (PTH-1R). Both of these receptors are established drug targets – GLP-1R for diabetes and PTH-1R for osteoporosis.
  • Financial ResultsTotal operating expenses for the quarter ended September 30, 2013 were $13.6 million and included non-cash expenses of $3.2 million related to rent expense and stock-based compensation. For the same period in 2012, total operating expenses were $14.5 million, which included non-cash rent and stock-based compensation expenses of $576,000.

    The decrease in total operating expenses for the quarter ended September 30, 2013 compared to the prior year quarter is primarily due to a litigation settlement expense of $3.95 million recorded in the same period in 2012, which was reimbursed by CCIC in the fourth quarter of 2012. For the quarter ended Septemb
    '/>"/>

    SOURCE Omeros Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
    2. Omeros to Present at the 12th Annual Needham Healthcare Conference
    3. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
    4. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
    5. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
    6. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
    7. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
    8. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
    9. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2014 Financial Results
    10. Attention Amarin Corporation plc Investors: Amarin Corporation plc Misled Investors According to a Newly Filed Class Action
    11. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2014)... , July 31, 2014 Nearly 20,000 ... th Annual Meeting & Clinical Lab Expo in ... meeting featured never-before-seen breakthroughs in diagnostic research and technology ... they need. As of Wednesday, July 30, ... AACC Annual Meeting & Clinical Lab Expo, with more ...
    (Date:7/31/2014)... have mapped the sound-processing part of the mouse brain ... and the trees in view. Their imaging technique allows ... within mice, and it enabled the team to watch ... other. The results, which represent a step toward better ... July 31 the journal Neuron . , In ...
    (Date:7/31/2014)... Calif. , July 31, 2014 Rogne ... San Francisco Bay Area , has acquired a ... of Oxford,s commercialisation company. The potent anti-inflammatory activity of ... at the University of Oxford,s Sir William ... company, which has raised over $1.5 million in seed ...
    (Date:7/31/2014)... , July 31, 2014 Research ... "Global Genomics Market 2014-2018" report to their ... Genomics is the study of the genetic material ... be a strong basis for the discovery and development ... human diseases or health conditions. Genomics is supported by ...
    Breaking Biology Technology:Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 3New mapping approach lets scientists zoom in and out as the brain processes sound 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2
    ... AvidBiotics Corp. announced the issuance of foundational ... massive diversity within precisely targeted sites of protein-encoding ... to as Diversity Generating Retroelements (DGR) and patents ... and in Europe (#1,173,995). UCLA and AvidBiotics ...
    ... Exchange Symbol: MS , EDMONTON, Nov. 12 /PRNewswire-FirstCall/ - ... operational results for the three and nine months ended ... license and collaboration agreement between BioMS Medical and Eli ... with the effect that all commercial rights to dirucotide ...
    ... Regado Biosciences, a privately held company leading the ... that David Mazzo, PhD, CEO and President, will be ... Conference at the St. Regis Hotel in New York ... (EST) on Tuesday, November 17 and will include an ...
    Cached Biology Technology:AvidBiotics Corp. Granted Key U.S. and European Patents on Unique Protein Modification Platform 2BioMS Medical Announces Third Quarter 2009 Results 2BioMS Medical Announces Third Quarter 2009 Results 3BioMS Medical Announces Third Quarter 2009 Results 4BioMS Medical Announces Third Quarter 2009 Results 5BioMS Medical Announces Third Quarter 2009 Results 6BioMS Medical Announces Third Quarter 2009 Results 7BioMS Medical Announces Third Quarter 2009 Results 8Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009 2
    (Date:8/1/2014)... Advances in stem cell research will provide enormous ... Basically, stem cells could replicate any other cells ... Alzheimer,s disease, repairing damaged spinal cords, treating kidney, ... whole. The potential for profit is staggering. Prof. ... that this field of research still faces myriad ...
    (Date:8/1/2014)... August 1, 2014 The Journal of Nutrition ... and Best Great Educational Material (GEM) awards, which were ... (SNEB) annual conference, "Nutrition Education Impact: Local to Global," ... These annual awards recognize the authors of the ... JNEB, as judged by members of the JNEB Journal ...
    (Date:8/1/2014)... at The Scripps Research Institute (TSRI) have identified a ... in brown fat cells. , The study, which ... the Proceedings of the National Academy of Sciences ... fat thermogenesis," which is of great interest to medical ... also protect against diabetes. , "This finding offers new ...
    Breaking Biology News(10 mins):Scripps Research Institute scientists find new calorie-burning switch in brown fat 2Scripps Research Institute scientists find new calorie-burning switch in brown fat 3
    ... Washington, D.C. (January 25, 2011) -- In ... displays, touch panels, electronic ink, and solar cells, ... physicists in Iran have created a spintronic device ... being pursued by the semiconductor and electronics industries ...
    ... theory of natural selection on the realization that genetic ... Some individuals are better adapted to a given environment ... pass on their genes to future generations. But exactly ... poses somewhat of a puzzle to evolutionary biologists. ...
    ... Duke University bioengineers have developed a new method ... DNA sequences. These novel sequences of recombinant DNA ... types of drugs and bioengineered tissues. Current methods for ... the researchers said, which has hindered the development of ...
    Cached Biology News:Armchair nanoribbons made into spintronic device 2Evolution by mistake 2Evolution by mistake 3Evolution by mistake 4New method for rapidly producing protein-polymers 2
    Purified anti-Fanconi anemia D2-Phosphorylated (Ser222)...
    A431 cells stimulated with EGF Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
    ... 'The Gene Construction KitTM allows graphic ... drawing options. It has an award winning ... DNA sequences in addition to providing sophisticated ... GCK was named the "Best Plasmid Mapping ...
    ... collects data from balances and scales with RS232 ... other program. If you can type the weight ... collection process Simple to use parser extracts ... , Add user information , Collect data at ...
    Biology Products: